drugset / Trial / NCT01573780
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the dose of smac mimetic TL32711 that is safe and tolerated when given with gemcitabine hydrochloride to patients with advanced cancer
Timeline
- Start
- 2012-04
- Primary completion
- 2013-09
- Completion
- —
Outcome
Outcome not reported
Stopped (Business): “Sponsor did not have funds to continue study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Birinapant | Small molecule | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |